Nutritional assessment contains several components because an individual's nutritional status cannot be defined by any single measure. Important components to consider include anthropometry, body ...

From biomarkers reflecting micronutrient status to dietary patterns indicative of overall dietary quality, a holistic approach to nutritional assessment is essential for informing evidence-based ...

This article explains how to carry out nutritional assessments in neonatal patients. The purpose of nutritional assessment is to document objective nutritional parameters, identify nutritional ...

However, the assessment of muscle mass ... comprehensive guidelines have been proposed to improve clinical nutrition and hydration in older adults. These guidelines recommend routine screening ...

Aims To determine the most reliable method for a nutritional assessment in a child with cerebral palsy with a GMFCS level IV-V. Methods The review is in four parts: A review of the reasons behind this ...

No universally accepted paediatric nutritional screening tool exists. This study aimed to evaluate validity and ease of use two new instruments, STAMP and STRONG, for the assessment of nutritional ...

Aims To identify nutritional issues experienced and develop a nutrition assessment tool to sensitively determine and deliver nutritional care to meet the needs of patients and carers. Methods A ...

Nutritional Life Cycle Assessment (nLCA) is a rapidly growing sub-framework of the LCA method which is aimed at identifing the trade-offs between environmental degradation potentials and adequate ...

Individualized nutritional strategies relying on risk assessment tools or biomarkers deserve further investigation in rigorously designed, large, multicenter, randomized, controlled trials.

The construct of malnutrition has three domains: intake or uptake of nutrition; body composition and physical and cognitive function. The objectives of this systematic review are to identify ...

Introduction Motor neurone disease (MND) is a fatal, progressive, neurodegenerative disease with a median survival from onset of symptoms of 4.32 years. No controlled trials indicate a benefit, ...